TScan Therapeutics (TCRX) Cash & Current Investments (2020 - 2026)

TScan Therapeutics (TCRX) has reported Cash & Current Investments for 7 consecutive years, with $128.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 49.12% year-over-year to $128.1 million; the TTM figure through Mar 2026 stood at $128.1 million (down 49.12% YoY), while the FY2025 annual figure was $152.4 million, down 47.47% from the prior year.
• Cash & Current Investments slipped to $128.1 million in Q1 2026 per TCRX's latest filing, from $152.4 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $297.7 million in Q2 2024 and bottomed at $95.6 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $187.8 million across 5 years, with a median of $184.5 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Current Investments jumped 70.26% — and 2026, when it tumbled 49.12%.
• TScan Therapeutics' Cash & Current Investments stood at $120.0 million in 2022, then soared by 60.0% to $192.0 million in 2023, then surged by 51.06% to $290.1 million in 2024, then tumbled by 47.47% to $152.4 million in 2025, then declined by 15.98% to $128.1 million in 2026.
• Business Quant data shows TCRX's Cash & Current Investments at $128.1 million in Q1 2026, $152.4 million in Q4 2025, and $184.5 million in Q3 2025.